War on Vaping Threatens Public Health

War on Vaping Threatens Public Health
Will the government hamstring what is potentially the most important public health innovation of the 21st century?

Last week, the Food and Drug Administration announced “historic action” against e-cigarette manufacturers for what it sees as an “epidemic” of vaping among teenagers. E-cigarette makers have 60 days to come up with plans to mitigate teenage use of their products or face civil or criminal prosecution as well as new regulations such as sales bans on some of their products. 

Such a move could reverse recent stop-smoking achievements. While smoking rates have been declining steadily over the last half century, the pace has dramatically picked up in recent years as e-cigarettes have gained popularity.

If regulators don’t get in the way, e-cigarettes can continue to chip away at the one-in-six Americans who still smoke. This would be a major victory for public health. Smoking is still responsible for one in every five deaths. That is nearly three times more than the combined number of suicide, overdose, and alcohol-related deaths, whose rise has been attributed to the decline in U.S. life expectancy.

E-cigarettes are a comparably safe alternative that help people quit smoking because they deliver nicotine through water vapor — without the tar, smoke, carbon monoxide, and countless carcinogens in cigarettes.



 
Sign Up for Our Email Newsletter

RECENT NEWS

Waiving COVID-19 Vaccine Patents: A Bad Idea and a Dangerous Precedent

Waiving COVID-19 Vaccine Patents: A Bad Idea and a Dangerous Precedent

Waiving patent protection discourages cutting-edge research investments, which in turn produce breakthrough treatments no...  Read more

'I'm hopeful for the future': Alzheimer's drug approved by FDA

'I'm hopeful for the future': Alzheimer's drug approved by FDA

Peter Pitts of CMPI and Dr. Ronald Petersen of the Mayo Clinic discuss the FDA's approval of aducanumab...  Read more

Biosimilar Strength vs. Potency: Avoiding a Regulatory Hobson’s Choice

Biosimilar Strength vs. Potency: Avoiding a Regulatory Hobson’s Choice

Biosimilars bring lower costs and greater access to the market for biological products, but FDA must determine a predicta...  Read more

DRUGWONKS BLOG